Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, RAPT Therapeutics Inc’s stock clocked out at $1.04, down -4.59% from its previous closing price of $1.09. In other words, the price has decreased by -$4.59 from its previous closing price. On the day, 0.62 million shares were traded.
Ratios:
To gain a deeper understanding of RAPT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.11 and its Current Ratio is at 21.11. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On December 26, 2024, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $10.
Stifel Downgraded its Buy to Hold on November 13, 2024, whereas the target price for the stock was revised from $7 to $2.
Stock Price History:
Over the past 52 weeks, RAPT has reached a high of $3.83, while it has fallen to a 52-week low of $0.71. The 50-Day Moving Average of the stock is 11.83%, while the 200-Day Moving Average is calculated to be -23.26%.
Shares Statistics:
A total of 132.01M shares are outstanding, with a floating share count of 68.99M. Insiders hold about 47.85% of the company’s shares, while institutions hold 51.92% stake in the company.
Earnings Estimates
The market rating for RAPT Therapeutics Inc (RAPT) is a result of the insights provided by 5.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.06 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.25 and -$0.43 for the fiscal current year, implying an average EPS of -$0.35. EPS for the following year is -$0.43, with 5.0 analysts recommending between -$0.25 and -$0.61.
